Trump signs order to expedite psychedelic drug research and access

Donald Trump recently announced reforms to accelerate access to medical research and treatment involving psychedelic drugs. During a signing ceremony at the White House, Trump signed an executive order directing the federal Food and Drug Administration (FDA) to expedite the review of drugs such as ibogaine, which veteran groups have identified as potentially beneficial for treating post-traumatic stress disorder (PTSD).

At the event, Trump stated, "If these turn out to be as good as people are saying, it’s going to have a tremendous impact on this country and other countries, too." The president also revealed that the U.S. would allocate $50 million towards federal research into ibogaine. The New York Times noted that Texas has already committed $50 million to studying the drug, which is derived from a central African shrub root.

Accompanying Trump were U.S. Health Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan. Kennedy, who has previously criticized the FDA for its stance on psychedelics, and Rogan, a proponent of responsible psychedelic use, both support the initiative. Trump added humor to the occasion, joking, "Can I have some please? I’ll take whatever it takes. I don’t have time to be depressed."

The strategic implications of this executive order are significant. By expediting the review process for psychedelic drugs, Trump positions his administration as a pioneer in mental health treatment, potentially appealing to a broad spectrum of voters, including veterans and those struggling with substance abuse. This move could also shift the landscape of drug policy in the U.S., as successful trials may lead to reclassification and wider acceptance of psychedelics.

What to watch: The upcoming clinical trial results for ibogaine and their potential impact on drug policy reform in the U.S.